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INTRODUCTION: The St George Hospital specialises in peritonectomy and hyperthermic intraperitoneal
chemotherapy (HIPEC) for treatment of intra-abdominal malignancies. Despite performing around 800
peritonectomyandHIPECprocedures,wehave rarely encountereddesmoplastic small roundcell tumours
(DSRCT). We present our experiences with DSRCT, and propose peritonectomy and HIPEC as a treatment
option for DSRCT.
PRESENTATION OF CASE: This is a case series of 3 cases. The ﬁrst case was a 26-year-old male who pre-
sented with appendicitis which we diagnosed as DSRCT and treated with peritonectomy and HIPEC. The
second case was a 14-year-old male referred to our centre for peritonectomy and HIPEC after initial pre-
sentation with a pelvic mass and treatment with chemotherapy. The third case was a 21-year-old male
referred to our centre for peritonectomy and HIPEC for recurrent DSRCT after previously being treated
with neoadjuvant chemotherapy and surgery without HIPEC.
DISCUSSION: DSRCT is a rare, almost exclusively intra-abdominal malignancy, which predominantly
affects young males. Survival prognosis remains poor in DSRCT despite conventional treatment with
surgery, chemotherapy and radiotherapy; however, HIPEC has offered promising survival results. Our
recurrenceswithperitonectomyandHIPECat 6months and15months are comparablewith the literature
of 8.85 months.
CONCLUSION: In our experience, patients with DSRCT who present with nodal involvement or recurrent
disease tend to recur early despite treatment with peritonectomy and HIPEC. Longer term follow up of
our patients and future studies involving HIPEC in DSRCT would be useful in assessing long-term clinical
outcomes and survival.
© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
The St George Hospital specialises in peritonectomy and hyper-
thermic intraperitoneal chemotherapy (HIPEC) for treatment of
intra-abdominal malignancies. Despite performing around 800
peritonectomy and HIPEC procedures, we have rarely encountered
desmoplastic small round cell tumours (DSRCT). We present our
experience with DSRCT and HIPEC in a series of three cases, and
propose peritonectomy andHIPEC as a treatment option for DSRCT.
1.1. Case 1
A 26-year-old gentleman presented with localised right iliac
fossapain after havinga colicky lower abdominal pain,which lasted
∗ Corresponding author. Tel.: +61 91133070.
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24h associated with anorexia, and nausea but no vomiting. His
bowel motions were regular, and he did not notice any blood, diar-
rhoea or tenesmus. He did not notice any weight loss and had
been well prior to this episode. Apart from a previous cholecys-
tectomy, his past medical and family history were unremarkable.
On examination he was afebrile, tachycardic, had a soft non dis-
tendedabdomenwithnopalpableherniasormasses.Hewas tender
over the right iliac fossa, hypogastrium and umbilical regions with
guarding, rebound tenderness, and positive Rovsing’s sign.
Given thehighclinical likelihoodof appendicitis, thepatientwas
taken for laparoscopic appendicectomy without imaging. Intraop-
eratively the appendix was found to be normal, however, a large
mass was found on the right hepatic ﬂexure with intra-abdominal
pus noted. Given this ﬁnding, the procedure was converted to an
open appendicectomy and right hemicolectomywith themass sent
off for histological assessment.
A 60mm mass was resected from the colon with margins of
30mm distally and 140mm proximally. No masses were seen
http://dx.doi.org/10.1016/j.ijscr.2014.09.022
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Fig. 1. (A)Nests of tumour cells surrounded by desmoplastic stroma (magniﬁcation: 100×). (B) Cellswith hyperchromic nuclei and scant cytoplasm (magniﬁcation: 400×). (C)
Immunohistochemical stain positive for cytokeratin (CAM 5.2). (D) Immunohistochemical stain positive for desmin, with immunoreactivity present in a typical perinuclear
dot-like Golgi pattern (large arrow).
on the serosal surfaces. The tumour involved the full thickness
of the colon wall invading through the serosal fat, just reaching
the serosal surface. No malignancy was identiﬁed within ﬁfteen
pericolic lymph nodes. Histology and immunohistochemistry con-
ﬁrmed a high grade undifferentiated DSRCT with a Ki67 of 30%.
The diagnosis of DSRCT was made on the basis of the tumour mor-
phology showing nests of tumour cells with hyperchromic nuclei
and scant cytoplasm surrounded by desmoplastic stroma, and
positive immunohistochemistry staining for desmin and cytoker-
atin (Fig. 1). Furthermore, ﬂuorescence in situ hybridisation (FISH)
techniques revealed positive EWSR1 arrangements, which further
supported our diagnosis. Interestingly, the tumour did not stain
positive with the WT1 antibody which is present in the majority of
DSRCT.
Staging workup with chest and abdomen CT, hepatic angiogram
CT and PET scans revealed a stage 1 DSRCT. Given the aggres-
sive nature of DSRCT, the patient was treated with a potentially
curative peritonectomy two weeks later with the aim of remov-
ing microscopic intraperitoneal disease and improving long term
survival. The intraoperative assessment revealed a peritoneal can-
cer index (PCI) of 4, with a small volume of disease in the pelvis.
A revision of the ileocolic anastamosis, omentectomy, pelvic peri-
tonectomy, excisionof theumbilicus and intraoperativeultrasound
for hepatic lesions was subsequently performed. The procedure
achieved a complete cytoreduction of the tumour with a complete-
ness of cytoreduction (CC) score of 0. Our procedure involvedHIPEC
with cisplatin at 41.5 ◦C for 90min. Postoperatively, urine output
was maintained at 100ml/h for 24h given the nephrotoxicity of
cisplatin. The repeat histopathology showed peritoneal deposits of
DSRCT in the ileocolic anastamosis, andpelvic peritoneum. The sur-
gical margins of resection were clear. No tumour was detected in
the lymph nodes examined.
The patient’s recovery was complicated by a pulmonary embo-
lus on postoperative day 10, for which heparin infusion was
initiatedandsubsequently switched to therapeutic enoxaparin. The
patient was discharged from hospital on postoperative day 19 and
commenced on systemic chemotherapy using cyclophosphamide,
doxorubicin and vincristine. The patient had one episode of febrile
neutropenia after his ﬁrst cycle of chemotherapy and was admit-
ted tohospital for intravenous antibiotics.Hehas since toleratedhis
cycles well and was on his fourth of nine cycles at the time of sub-
missionandwould continuewithongoingoncologist followup. The
patient had repeat colonoscopies and PET scanswith no evidence of
recurrence at 6 months post peritonectomy. He remained asymp-
tomaticwith ECOGperformance status grade 0, andwas continuing
with gym training.
1.2. Case 2
A 14-year-old male was referred to our unit with stage 2 DSRCT
after being treated with 11 weeks of vincristine, doxorubicin,
ifosfamide, and etoposide. He originally presented with a large
pelvic mass which was compressing against his right ureter,
bladder and prostate. He was referred to our centre after his initial
chemotherapy and had an intraoperative PCI of 12. We performed
a laparotomy for right diaphragm strip, cholecystectomy, right
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Table 1
shows published studies on survival outcomes of DSRCT, including the study out line and survival results.
Author Study outline Survival
Hayes-Jordan et al. [1] 8 patients treated with surgery +HIPEC vs. 16 patients treated
with chemotherapy± radiation therapy or surgery alone
71% 3 year survival with HIPEC
26% 3 year survival without HIPEC
Mean relapse free survival 8.85 months (HIPEC) versus 5.46
months (No HIPEC)
Lal et al. [15] 66 patients with histologically diagnosed DSRCT 58% 3 year survival in patients with complete surgical
resection, chemotherapy and radiotherapy
0% 3 year survival in patients without surgery
Desai et al. [16] 31 patients treated with chemotherapy, surgery and radiation
therapy
20% 5 year survival
50% 3 year survival
24% 3 year progression free survival
Liping et al. [17] 18 patients treated with chemotherapy and surgery 27.29% 5 year survival
27.29% 3 year survival
52.36%, 1 year survival
Saab et al. [18] 11 patients treated chemotherapy and surgery 21.1% 5 year survival
Ordón˜ez [19] 39 patients with histologically diagnosed DSRCT with surgical
debulking. 35 available to follow up, 25 deaths at time of
publication
Mean survival 25.2 months
hemicolectomy, anterior resection of the rectum, urinary bladder
strip, and lymph node dissections, to remove all visible tumours.
We then performed HIPEC with Cisplatin at 41.5 ◦C for 90min. The
histopathology conﬁrmed DSRCT with a Ki-67 of 20–30%, with
clear resectionmargins butmetastatic disease in the right common
iliac vein lymph nodes. Post operative recovery was complicated
by haemorrhage from the right psoas, for which we performed
a laparotomy for haemostasis and evacuation of the blood clot.
Despite ongoing chemotherapy with irinotecan/temozomide and
external beam radiation therapy, the patient developed recurrence
in the liver and right iliac lymph node chain at 15 months after
our procedure, as evident on PET scans, and he would continue
with ongoing oncologist follow up. The patient was asymptomatic,
ECOG grade 0 and competing in Go Kart racing at 20 months after
initial diagnosis.
1.3. Case 3
A 21-year-old male was referred to our unit for recurrence
of stage 1 DSRCT. He initially presented 17 months prior with 3
months of increasing left inguinal lymphadenopathy associated
with pain, but otherwise asymptomatic. His biopsywas positive for
DSRCT and he was subsequently treated with vincristine, doxyru-
bicin, cyclophosphamide, alphosphomide and etoposide, followed
by surgical resection of the mass. This recurred in the pelvis 6
months later and he was referred to our centre. Had an intra-
operative PCI of 5 and we performed a laparotomy for removal
of all visible tumour from the rectum, iliac vessels, obturator
nerve, pelvic peritoneum, and performed aortic node dissection.
We then performed HIPEC with cisplatin at 41.5 ◦C for 90min. The
histopathology conﬁrmed DSRCT with a Ki-67 of 5–20%, with clear
resection margins and metastatic disease in 6/6 lymph nodes. His
post operative stay was complicated by bowel obstruction which
was treated conservatively. Despite ongoing chemotherapy with
irinotecan/temozomide, the patient developed recurrence in the
left external iliac and para-aortic lymph nodes 6 months after
our procedure, as evident on PET scans, and he would continue
with ongoing oncologist followup. The patient remained energetic,
asymptomatic, ECOG grade 0 and was working on a ranch at 25
months after initial diagnosis.
2. Discussion
DSRCT is a rare sarcoma with fewer than 200 cases reported
between 1989 and 2010.1 This highly aggressive sarcoma pre-
dominantly occurs in males aged between 5 and 35.2,3 It involves
translocation t(11; 22) (p13; q12), which fuses the N-terminus of
the Ewing sarcoma (EWS) gene to the C-terminus of the Wilms
tumour (WT1) gene, resulting in a EWSR1/WT1 fusion product and
activation of the PI3K/Akt/mTOR pathway.4,5
Macroscopically, DSRCT show areas of necrosis and may also
have myxoid changes.2 Microscopically, DSRCT has a nesting
pattern of growth with focal rhabdoid features and intense
desmoplastic reaction.6 A distinctive feature of DSRCT is its diver-
gent differentiation that immunohistochemically stain positive for
epithelial (keratin, epithelial membrane antigen), mesenchymal
(vimentin), neural (neuron-speciﬁc enolase, CD56), and myogenic
(desmin) markers.6,7 Interestingly, DSRCT almost always stain pos-
itive with WT1 antibodies, which detects the WT1 component of
the EWSR1/WT1 fusion product.8 Even though our ﬁrst case did
not stain positive with WT1 antibodies, the diagnosis of DSRCT
was made based on morphology, positive cytokeratin and desmin
staining showing divergent differentiation, and positive FISH for
the EWSR component of the mutation.
DSRCTs are located almost exclusively in intra-abdominal loca-
tions and classically involve a large intra-abdominal mass in the
retroperitoneum, pelvis, omentum or mesentery, with diffuse
peritoneal deposits that spread along peritoneal and mesothelial
surfaces.2,6 DSRCT directly spreads to various organs including
liver, pancreas, spleen, and testes, with no consistent pattern of
organ involvements, and can metastases to lung, and lymph nodes
of the groin, neck and mediastinum.9,10 In rare cases, primary
DSRCT have been reported outside of the abdominal cavity to affect
thorax, and head and neck regions.10,11
Diagnostic investigations include abdominal imaging, either
with computed tomography (CT), or magnetic resonance imaging
(MRI) to assess peritoneal and extra abdominal lesions, followed
by a histological diagnosis with tissue samples from laparoscopy.2
The current proposed staging system based on comparison of out-
comes involves stage 1: PCI <12, without liver metastases; stage 2:
PCI≥12 without liver metastases; stage 3: liver metastases; and
stage 4: extra abdominal metastases.1
There is currently no standardised treatment option for DSRCT.
Traditional treatments include induction chemotherapy using
agents such as cyclophosphamide, doxorubicin, vincristine, ifos-
famide and etoposide,12 followed by aggressive debulking and
external beam radiotherapy.13 Despite treatment, survival prog-
nosis remains poor (Table 1), with most patients experiencing
resistant and recurrent disease before end of life.14,15 The data
on use of HIPEC in DSRCT is scarce, however, Hayes-Jordan et al.
showed that HIPEC has improve survival outcomes with patients
receiving neoadjuvant chemotherapy followed by cytoreductive
surgery and HIPEC having a 3 year survival of 71% compared to 26%
(p=0.021) in patients who did not receive surgery or HIPEC.1 Our
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follow up has been shorter and hence we were unable to make a
direct comparison in terms of survival. Our recurrences at 6months
and15monthsare comparable to themeanof8.85months reported
by Hayes-Jordan et al. (2010).1 Our remaining patient had no dis-
ease recurrence after 6 months and we hope for better outcomes
given that he had no nodal disease, which is associated with bet-
ter outcomes.3 Our patients all had favourable prognostic factors
including, young age at diagnosis, and high functional status at
time of diagnosis,3 and all three patients have survived with good
function and quality of life.
3. Conclusion
Survival prognosis remains poor in DSRCT despite conven-
tional treatment with surgery, chemotherapy and radiotherapy;
however, HIPEC has offered promising survival results. In our expe-
rience, patientswithDSRCTwhopresentwithnodal involvementor
recurrent disease tend to recur early despite treatment with peri-
tonectomy and HIPEC. Despite this recurrence, our patients have
recovered well following peritonectomy and HIPEC treatments.
Longer term follow up of our patients and future studies involving
peritonectomy and HIPEC in DSRCT would be useful in assessing
long-term clinical outcomes and survival.
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